Two presentations at the World Conference on Lung Cancer will make a big difference for at least four different drugmakers.
News & Analysis: Blueprint Medicines
It looks like this biotech has what big-pharma companies have been eager to acquire.
News from key competitors sent this company's shares reeling.
The biopharma reported encouraging data from a phase 1 trial. Er, wait, what?